Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
October 28, 2009

Oncodesign to Provide Sanofi-Aventis with Exclusive Cancer Models

  • Oncodesign signed a two-year service contract with sanofi-aventis, under which it will develop and provide the latter with exclusive experimental tumor-derived models for different types of cancer. Philippe Genne, Oncodesign CEO, suggests the the contract represents “a first for a service company, since it is a long-term collaboration that calls for us to supply experimental models to sanofi-aventis.”

    Oncodesign says that unlike traditional cancer models derived from cultured cell lines, its technology is based on patient-derived tumor tissue. Oncodesign has previously worked with sanofi-aventis on the CReMEC (creating a resource center for experimental cancer models) program. It was initiated in 2005 as part of the Medicin Paris Region competition pole to develop and characterize experimental models of colon cancer.

Related content

  • You’re all set! Thank you for subscribing to GEN Highlights.